Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O\'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D. Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2023 Dec 01;29(23):4784-4796 PMID: 37463058 PMCID: PMC10690096 SCOPUS ID: 2-s2.0-85178651085 07/18/2023
Pan J, Xiong D, Zhang Q, Palen K, Shoemaker RH, Johnson B, Sei S, Wang Y, You M. Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention. Front Immunol. 2023;14:1036563 PMID: 36875137 PMCID: PMC9982083 SCOPUS ID: 2-s2.0-85149504680 03/07/2023
Chu Y, Milner J, Lamb M, Maryamchik E, Rigot O, Ayello J, Harrison L, Shaw R, Behbehani GK, Mardis ER, Miller K, Prakruthi Rao Venkata L, Chang H, Lee D, Rosenthal E, Kadauke S, Bunin N, Talano JA, Johnson B, Wang Y, Cairo MS. Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes. J Infect Dis. 2023 Mar 28;227(6):788-799 PMID: 36583990 SCOPUS ID: 2-s2.0-85151044080 12/31/2022
Chu Y, Talano JA, Baxter-Lowe LA, Verbsky JW, Morris E, Mahanti H, Ayello J, Keever-Taylor C, Johnson B, Weinberg RS, Shi Q, Moore TB, Fabricatore S, Grossman B, van de Ven C, Shenoy S, Cairo MS. Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease. Front Immunol. 2022;13:1055497 PMID: 36569951 PMCID: PMC9780682 SCOPUS ID: 2-s2.0-85144637382 12/27/2022
Knight JM, Hackett E, Szabo A, Wu R, Sauber G, Johnson B, Cusatis RN, Aughey E, Cole SW, Hillard CJ, Shah NN. Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes. Haematologica. 2023 Feb 01;108(2):588-593 PMID: 36200427 PMCID: PMC9890001 SCOPUS ID: 2-s2.0-85147234722 10/07/2022
Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN. Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. Am J Hematol. 2022 Dec;97(12):1580-1588 PMID: 36068950 SCOPUS ID: 2-s2.0-85138335080 09/08/2022
Taylor MR, Hillard CJ, Drobyski WR, Szabo A, Johnson BD, Zhu F, Raison CL, Cole SW, Knight JM. The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation. Brain Behav Immun Health. 2022 Aug;23:100480 PMID: 35757656 PMCID: PMC9213229 SCOPUS ID: 2-s2.0-85133379996 06/28/2022
Zurko JC, Xu H, Chaney K, Schneider D, Szabo A, Hari P, Johnson BD, Shah NN. Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. Cytotherapy. 2022 Aug;24(8):767-773 PMID: 35597752 SCOPUS ID: 2-s2.0-85130432792 05/22/2022
Zurko JC, Johnson BD, Aschenbrenner E, Fenske TS, Hamadani M, Hari P, Shah NN. Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. JAMA Oncol. 2022 May 01;8(5):773-775 PMID: 35266965 PMCID: PMC8914887 SCOPUS ID: 2-s2.0-85126591538 03/11/2022
Huang M, Xiong D, Pan J, Zhang Q, Wang Y, Myers CR, Johnson BD, Hardy M, Kalyanaraman B, You M. Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria-Targeted Atovaquone. Adv Sci (Weinh). 2022 Apr;9(12):e2101267 PMID: 35243806 PMCID: PMC9036031 SCOPUS ID: 2-s2.0-85125564839 03/05/2022